Identification

Name
Gliquidone
Accession Number
DB01251
Type
Small Molecule
Groups
Approved, Investigational
Description

Gliquidone is an anti-diabetic drug in the sulfonylurea class. It is used in the treatment of diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.

Structure
Thumb
Synonyms
  • Glurenorm
External IDs
ARDF 26
International/Other Brands
Devotan (Menarini) / Fordiab (Hexpharm Jaya) / Glidiab (Soho) / Glunormal (Ying Yuan) / Glurenor (Guidotti) / Glurenorm (Boehringer Ingelheim) / Jie Shi (Tianjin Institute of Pharmaceutical Research Pharmaceutical) / Ka Rui Lin (Anjielun) / Lodem (Dexa Medica)
Categories
UNII
C7C2QDD75P
CAS number
33342-05-1
Weight
Average: 527.632
Monoisotopic: 527.209006493
Chemical Formula
C27H33N3O6S
InChI Key
LLJFMFZYVVLQKT-UHFFFAOYSA-N
InChI
InChI=1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)
IUPAC Name
1-cyclohexyl-3-{4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]benzenesulfonyl}urea
SMILES
COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O

Pharmacology

Indication

Used in the treatment of diabetes mellitus type 2.

Structured Indications
Not Available
Pharmacodynamics

Gliquidone is an anti-diabetic drug in the sulfonylurea class. In patients with diabetes mellitus, there is a deficiency or absence of a hormone manufactured by the pancreas called insulin. Insulin is the main hormone responsible for the control of sugar in the blood. Gliquidone is an antidiabetic medication which is used in those patients with adult maturity onset or non-insulin dependent diabetes (NIDDM). It works by lowering blood sugar levels by stimulating the production and release of insulin from the pancreas. It also promotes the movement of sugar from the blood into the cells in the body which need it.

Mechanism of action

The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.

TargetActionsOrganism
AATP-binding cassette sub-family C member 8
inhibitor
Human
AATP-sensitive inward rectifier potassium channel 8
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

The mean terminal half-life was approximately 8 hours (range 5.7-9.4 hours)

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololAcebutolol may increase the hypoglycemic activities of Gliquidone.Approved
AcenocoumarolGliquidone may increase the anticoagulant activities of Acenocoumarol.Approved
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Gliquidone.Approved
AlogliptinAlogliptin may increase the hypoglycemic activities of Gliquidone.Approved
AlprenololAlprenolol may increase the hypoglycemic activities of Gliquidone.Approved, Withdrawn
Aluminium clofibrateAluminium clofibrate may increase the hypoglycemic activities of Gliquidone.Experimental
AripiprazoleThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
Arsenic trioxideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Asenapine.Approved
AtazanavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypoglycemic activities of Gliquidone.Approved
AtorvastatinAtorvastatin may increase the hypoglycemic activities of Gliquidone.Approved
BefunololBefunolol may increase the hypoglycemic activities of Gliquidone.Experimental
BendroflumethiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Bendroflumethiazide.Approved
BetamethasoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the hypoglycemic activities of Gliquidone.Approved
BevantololBevantolol may increase the hypoglycemic activities of Gliquidone.Approved
BezafibrateBezafibrate may increase the hypoglycemic activities of Gliquidone.Approved
BisoprololBisoprolol may increase the hypoglycemic activities of Gliquidone.Approved
BopindololBopindolol may increase the hypoglycemic activities of Gliquidone.Approved
BrexpiprazoleThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Brexpiprazole.Approved
BucindololBucindolol may increase the hypoglycemic activities of Gliquidone.Investigational
BufuralolBufuralol may increase the hypoglycemic activities of Gliquidone.Experimental, Investigational
BumetanideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Bumetanide.Approved
BupranololBupranolol may increase the hypoglycemic activities of Gliquidone.Approved
BuserelinThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Buserelin.Approved
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Gliquidone.Approved
CarbocisteineThe risk or severity of adverse effects can be increased when Gliquidone is combined with Carbocisteine.Approved, Investigational
CarteololCarteolol may increase the hypoglycemic activities of Gliquidone.Approved
CarvedilolCarvedilol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
CeliprololCeliprolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
CeritinibThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ceritinib.Approved
ChloramphenicolThe metabolism of Gliquidone can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpropamideGliquidone may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Chlorthalidone.Approved
CimetidineThe serum concentration of Gliquidone can be increased when it is combined with Cimetidine.Approved
CiprofibrateCiprofibrate may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
ClofibrateClofibrate may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
ClofibrideClofibride may increase the hypoglycemic activities of Gliquidone.Experimental
CloranololCloranolol may increase the hypoglycemic activities of Gliquidone.Experimental
ClorindioneGliquidone may increase the anticoagulant activities of Clorindione.Experimental
ClozapineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Clozapine.Approved
CorticotropinThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Cortisone acetate.Approved
CyclopenthiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Cyclopenthiazide.Experimental
Cyproterone acetateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Dabrafenib.Approved
DanazolThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Danazol.Approved
DarunavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Darunavir.Approved
DesogestrelThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Desogestrel.Approved
DexamethasoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Diazoxide.Approved
DicoumarolGliquidone may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Dienogest.Approved
DiphenadioneGliquidone may increase the anticoagulant activities of Diphenadione.Experimental
DisopyramideGliquidone may increase the hypoglycemic activities of Disopyramide.Approved
DrospirenoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Drospirenone.Approved
DulaglutideDulaglutide may increase the hypoglycemic activities of Gliquidone.Approved
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Gliquidone.Approved
EpanololEpanolol may increase the hypoglycemic activities of Gliquidone.Experimental
EpinephrineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Epinephrine.Approved, Vet Approved
ErtugliflozinErtugliflozin may increase the hypoglycemic activities of Gliquidone.Approved
EsmololEsmolol may increase the hypoglycemic activities of Gliquidone.Approved
EstradiolThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Etacrynic acid.Approved
EthanolThe risk or severity of adverse effects can be increased when Gliquidone is combined with Ethanol.Approved
Ethinyl EstradiolThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethyl biscoumacetateGliquidone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ethynodiol diacetate.Approved
EtofibrateEtofibrate may increase the hypoglycemic activities of Gliquidone.Approved
EtonogestrelThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Etonogestrel.Approved, Investigational
EverolimusThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Everolimus.Approved
ExenatideExenatide may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
FenofibrateFenofibrate may increase the hypoglycemic activities of Gliquidone.Approved
Fenofibric acidFenofibric acid may increase the hypoglycemic activities of Gliquidone.Approved
FluconazoleThe serum concentration of Gliquidone can be increased when it is combined with Fluconazole.Approved
FludrocortisoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Fludrocortisone.Approved
FluindioneGliquidone may increase the anticoagulant activities of Fluindione.Investigational
FosamprenavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Fosamprenavir.Approved
FurosemideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Furosemide.Approved, Vet Approved
GemfibrozilGemfibrozil may increase the hypoglycemic activities of Gliquidone.Approved
GliclazideGliquidone may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGliquidone may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideGliquidone may increase the hypoglycemic activities of Glipizide.Approved
GlyburideGliquidone may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Goserelin.Approved
HistrelinThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Histrelin.Approved
HydrochlorothiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IloperidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Iloperidone.Approved
IndapamideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Indapamide.Approved
IndenololIndenolol may increase the hypoglycemic activities of Gliquidone.Withdrawn
IndinavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Indinavir.Approved
Insulin AspartGliquidone may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirGliquidone may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineGliquidone may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineGliquidone may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanGliquidone may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproGliquidone may increase the hypoglycemic activities of Insulin Lispro.Approved
LabetalolLabetalol may increase the hypoglycemic activities of Gliquidone.Approved
LandiololLandiolol may increase the hypoglycemic activities of Gliquidone.Investigational
LanreotideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lanreotide.Approved
LeuprolideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the hypoglycemic activities of Gliquidone.Approved
LevonorgestrelThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LinagliptinLinagliptin may increase the hypoglycemic activities of Gliquidone.Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Gliquidone.Approved, Nutraceutical
LiraglutideLiraglutide may increase the hypoglycemic activities of Gliquidone.Approved
LopinavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lopinavir.Approved
LurasidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lurasidone.Approved
MecaserminGliquidone may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrogestoneThe serum concentration of Gliquidone can be decreased when it is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MepindololMepindolol may increase the hypoglycemic activities of Gliquidone.Experimental
MestranolThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Mestranol.Approved
MethotrimeprazineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methyclothiazide.Approved
MethylprednisoloneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MetipranololMetipranolol may increase the hypoglycemic activities of Gliquidone.Approved
MetolazoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Metolazone.Approved
MetoprololMetoprolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
MetreleptinMetreleptin may increase the hypoglycemic activities of Gliquidone.Approved
MiconazoleMiconazole may increase the hypoglycemic activities of Gliquidone.Approved, Investigational, Vet Approved
MifepristoneGliquidone may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
NadololNadolol may increase the hypoglycemic activities of Gliquidone.Approved
NateglinideGliquidone may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololNebivolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
NelfinavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Nelfinavir.Approved
NiacinThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NilotinibThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Nilotinib.Approved, Investigational
NorethisteroneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Norethisterone.Approved
NorgestimateThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Norgestimate.Approved
OctreotideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Octreotide.Approved, Investigational
OlanzapineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Olanzapine.Approved, Investigational
OxprenololOxprenolol may increase the hypoglycemic activities of Gliquidone.Approved
PaliperidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Paliperidone.Approved
PasireotideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Pasireotide.Approved
PenbutololPenbutolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
PentamidineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Pentamidine.Approved
PhenindioneGliquidone may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonGliquidone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PindololPindolol may increase the hypoglycemic activities of Gliquidone.Approved
PioglitazonePioglitazone may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
PiperazineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Pipotiazine.Approved, Investigational
Platelet Activating FactorPlatelet Activating Factor may increase the hypoglycemic activities of Gliquidone.Experimental
PolythiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Polythiazide.Approved
PractololPractolol may increase the hypoglycemic activities of Gliquidone.Approved
PrednisoloneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of heart failure can be increased when Pregabalin is combined with Gliquidone.Approved, Illicit, Investigational
ProbenecidThe protein binding of Gliquidone can be decreased when combined with Probenecid.Approved
ProgesteroneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Progesterone.Approved, Vet Approved
PropranololPropranolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
QuetiapineThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Quinethazone.Approved
QuinineGliquidone may increase the hypoglycemic activities of Quinine.Approved
RanitidineThe serum concentration of Gliquidone can be increased when it is combined with Ranitidine.Approved
RepaglinideGliquidone may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RifampicinThe serum concentration of Gliquidone can be decreased when it is combined with Rifampicin.Approved
RisperidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ritonavir.Approved, Investigational
RonifibrateRonifibrate may increase the hypoglycemic activities of Gliquidone.Experimental
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
SaquinavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Saquinavir.Approved, Investigational
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Gliquidone.Approved
SimfibrateSimfibrate may increase the hypoglycemic activities of Gliquidone.Experimental
SirolimusThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Sirolimus.Approved, Investigational
SitagliptinSitagliptin may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
SotalolSotalol may increase the hypoglycemic activities of Gliquidone.Approved
SulfadiazineGliquidone may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleGliquidone may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleGliquidone may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SunitinibGliquidone may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Tacrolimus.Approved, Investigational
TalinololTalinolol may increase the hypoglycemic activities of Gliquidone.Investigational
TemsirolimusThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Temsirolimus.Approved
TertatololTertatolol may increase the hypoglycemic activities of Gliquidone.Experimental
TimololTimolol may increase the hypoglycemic activities of Gliquidone.Approved
TioclomarolGliquidone may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Tipranavir.Approved, Investigational
TolazamideGliquidone may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideGliquidone may increase the hypoglycemic activities of Tolbutamide.Approved
TorasemideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Torasemide.Approved
TriamcinoloneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TroglitazoneTroglitazone may increase the hypoglycemic activities of Gliquidone.Investigational, Withdrawn
UbidecarenoneThe therapeutic efficacy of Gliquidone can be increased when used in combination with Ubidecarenone.Approved, Investigational, Nutraceutical
VildagliptinVildagliptin may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
VoriconazoleThe serum concentration of Gliquidone can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Vorinostat.Approved, Investigational
WarfarinGliquidone may increase the anticoagulant activities of Warfarin.Approved
ZiprasidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ziprasidone.Approved
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,708,486.

General References
Not Available
External Links
Human Metabolome Database
HMDB15381
KEGG Drug
D02430
PubChem Compound
91610
PubChem Substance
46508425
ChemSpider
82719
ChEBI
93416
ChEMBL
CHEMBL383634
Therapeutic Targets Database
DAP000924
PharmGKB
PA164744895
Wikipedia
Gliquidone
ATC Codes
A10BB08 — Gliquidone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)180-182U.S. Patent 3,708,486.
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0022 mg/mLALOGPS
logP3.59ALOGPS
logP4.14ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.32ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area121.88 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity139.48 m3·mol-1ChemAxon
Polarizability57.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9157
Blood Brain Barrier+0.625
Caco-2 permeable-0.6185
P-glycoprotein substrateSubstrate0.7457
P-glycoprotein inhibitor IInhibitor0.6115
P-glycoprotein inhibitor IIInhibitor0.805
Renal organic cation transporterNon-inhibitor0.7921
CYP450 2C9 substrateSubstrate0.5166
CYP450 2D6 substrateNon-substrate0.8162
CYP450 3A4 substrateSubstrate0.594
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.6454
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.7961
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5173
Ames testNon AMES toxic0.6124
CarcinogenicityNon-carcinogens0.7477
BiodegradationNot ready biodegradable0.8693
Rat acute toxicity2.3506 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8418
hERG inhibition (predictor II)Inhibitor0.6182
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0000190000-4154029e3d9f7cf38376
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0422900000-64e5b1e1949d772ce08b

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,3-isoquinolinediones. These are isoquinoline derivatives carrying one C=O group at positions 1, and 3 respectively.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoquinolines and derivatives
Sub Class
1,3-isoquinolinediones
Direct Parent
1,3-isoquinolinediones
Alternative Parents
Isoquinolones and derivatives / Tetrahydroisoquinolines / Benzenesulfonamides / Benzenesulfonyl compounds / Anisoles / Sulfonylureas / Alkyl aryl ethers / N-substituted carboxylic acid imides / Organosulfonic acids and derivatives / Aminosulfonyl compounds
show 8 more
Substituents
1,3-isoquinolinedione / Isoquinolone / Tetrahydroisoquinoline / Benzenesulfonamide / Benzenesulfonyl group / Anisole / Alkyl aryl ether / Sulfonylurea / Monocyclic benzene moiety / Benzenoid
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sulfonylurea receptor activity
Specific Function
Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.
Gene Name
ABCC8
Uniprot ID
Q09428
Uniprot Name
ATP-binding cassette sub-family C member 8
Molecular Weight
176990.36 Da
References
  1. Gribble FM, Ashcroft FM: Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism. 2000 Oct;49(10 Suppl 2):3-6. [PubMed:11078468]
  2. Harrower A: Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. Metabolism. 2000 Oct;49(10 Suppl 2):7-11. [PubMed:11078469]
  3. Lawrence CL, Proks P, Rodrigo GC, Jones P, Hayabuchi Y, Standen NB, Ashcroft FM: Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia. 2001 Aug;44(8):1019-25. [PubMed:11484080]
  4. Reimann F, Ashcroft FM, Gribble FM: Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9. [PubMed:11574406]
  5. Proks P, Reimann F, Green N, Gribble F, Ashcroft F: Sulfonylurea stimulation of insulin secretion. Diabetes. 2002 Dec;51 Suppl 3:S368-76. [PubMed:12475777]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Inward rectifier potassium channel activity
Specific Function
This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their...
Gene Name
KCNJ8
Uniprot ID
Q15842
Uniprot Name
ATP-sensitive inward rectifier potassium channel 8
Molecular Weight
47967.455 Da
References
  1. Szewczyk A, Wojcik G, Lobanov NA, Nalecz MJ: The mitochondrial sulfonylurea receptor: identification and characterization. Biochem Biophys Res Commun. 1997 Jan 23;230(3):611-5. [PubMed:9015372]
  2. Sato T, Costa AD, Saito T, Ogura T, Ishida H, Garlid KD, Nakaya H: Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8. Epub 2005 Sep 20. [PubMed:16174795]
  3. Hill RA, Rudra S, Peng B, Roane DS, Bounds JK, Zhang Y, Adloo A, Lu T: Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113. [PubMed:12670661]

Drug created on March 30, 2007 08:35 / Updated on November 09, 2017 02:58